Nevro Corp. (NYSE:NVRO) – Equities research analysts at Leerink Swann decreased their Q1 2019 earnings estimates for Nevro in a research note issued on Thursday. Leerink Swann analyst D. Antalffy now forecasts that the medical equipment provider will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. Leerink Swann currently has a “Outperform” rating and a $110.00 target price on the stock. Leerink Swann also issued estimates for Nevro’s Q2 2019 earnings at $0.09 EPS and FY2020 earnings at $0.89 EPS.
Nevro (NYSE:NVRO) last issued its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company had revenue of $82.26 million during the quarter, compared to analyst estimates of $80.50 million. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The firm’s revenue for the quarter was up 35.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.14) earnings per share.
Shares of Nevro (NYSE NVRO) traded down $0.82 during trading on Monday, reaching $74.00. The company had a trading volume of 511,800 shares, compared to its average volume of 507,350. Nevro has a 52 week low of $65.82 and a 52 week high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59.
In other news, Director Michael F. Demane sold 25,000 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $87.73, for a total transaction of $2,193,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total value of $525,770.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,467 shares of company stock valued at $5,576,679. Company insiders own 9.10% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in NVRO. Ameritas Investment Partners Inc. boosted its holdings in Nevro by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after purchasing an additional 358 shares during the period. PNC Financial Services Group Inc. purchased a new position in Nevro in the second quarter valued at $190,000. US Bancorp DE boosted its holdings in Nevro by 412.4% in the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 2,099 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Nevro in the third quarter valued at $211,000. Finally, Prudential Financial Inc. boosted its holdings in Nevro by 13.8% in the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock valued at $214,000 after purchasing an additional 350 shares during the period.
TRADEMARK VIOLATION WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/04/q1-2019-earnings-estimate-for-nevro-corp-issued-by-leerink-swann-nvro.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
What are top analysts saying about Nevro Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nevro Corp. and related companies.